<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>INTRODUCTION: LFA-1 is an <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> molecule which belongs to the β2-integrin family </plain></SENT>
<SENT sid="1" pm="."><plain>Overexpression of LFA-1 in hepatic natural killer cells has been associated with <z:mp ids='MP_0006042'>increased apoptosis</z:mp> of neoplastic cells in <z:e sem="disease" ids="C1527249,C0009402" disease_type="Neoplastic Process" abbrv="">colorectal cancer</z:e> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e>); moreover, studies in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> have linked LFA-1 overexpression in neoplastic cells with vascular intrusion through <z:e sem="disease" ids="C0001511" disease_type="Disease or Syndrome;Acquired Abnormality" abbrv="">adhesion</z:e> to endothelial cells, thus implying a possible role in creation of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="2" pm="."><plain>AIMS AND METHODS: We studied the expression of LFA-1 in a series of 82 patients with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>A standard three-step immunohistochemical analysis was performed on formalin-fixed, paraffin-embedded tissue sections </plain></SENT>
<SENT sid="4" pm="."><plain>An IgG2a anti-CD11a monoclonal antibody was used </plain></SENT>
<SENT sid="5" pm="."><plain>Cases were characterized according to clinicopathological variables including sex, age, <z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> localization, size, grade, Dukes stage, wall invasion, and presence of metastatic lymph nodes (mLNs) or distal <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastases</z:e> </plain></SENT>
<SENT sid="6" pm="."><plain>RESULTS: LFA-1 was expressed at the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> site in 51 cases and 6/33 cases with metastatic lymphnodes </plain></SENT>
<SENT sid="7" pm="."><plain>In Dukes D cases (n = 4), only one case was LFA-1(+) </plain></SENT>
<SENT sid="8" pm="."><plain>LFA-1 expression at the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> site was associated with the absence of <z:e sem="disease" ids="C0027627" disease_type="Neoplastic Process" abbrv="mets">metastatic disease</z:e> and with Dukes B stage </plain></SENT>
<SENT sid="9" pm="."><plain>However, in those cases with LFA-1 expression in <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> cells in mLNs, this was associated with its expression at the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> site </plain></SENT>
<SENT sid="10" pm="."><plain>CONCLUSION: The positive association of LFA-1 expression in mLNs when the <z:e sem="disease" ids="C0677930" disease_type="Neoplastic Process" abbrv="">primary tumor</z:e> site is also LFA-1(+) could imply an adaptation advantage of this specific cellular clone to its micro-environment, predisposing it to creation of mLNs, pointing to a role for LFA-1 in creation of mLNs in <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">CRC</z:e> </plain></SENT>
</text></document>